Galvus

Galvus is manufactured by Novartis Corporation for reduction in blood sugar for up to one year.

Galvus lowers blood sugar by targeting islet dysfunction. Galvus helps improve the ability for islet’s alpha and beta cells to appropriately respond to sugar in the blood.

On November 7, 2007, Novartis AG announced that high doses of its diabetes drug, Galvus, could cause liver-safety problems. The announcement has delayed the drug’s path to approval and has raised questions about its future. Novartis said it would seek a revision to fix the problem before introducing it in Europe.

Source: “Novartis Diabetes Drug Delayed,” Reuters, November 7, 2007.